The phar­ma in­dus­try's rep hits ab­solute. rock. bot­tom.

Af­ter two years of be­ing pil­lo­ried by the pres­i­dent and law­mak­ers for drug pric­ing, spark­ing head­lines about huge judg­ments levied for trig­ger­ing the opi­oid epi­dem­ic (J&J) and hid­ing ma­nip­u­lat­ed da­ta dur­ing an FDA re­view (No­var­tis), it may come as no sur­prise to hear that the in­dus­try’s rep­u­ta­tion has suf­fered some.

But it’s worse than that.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER